Suppr超能文献

一种人源单克隆免疫球蛋白M可降低全身性肺炎球菌感染小鼠模型中的菌血症和炎症反应。

A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection.

作者信息

Fabrizio Kevin, Groner Abraham, Boes Marianne, Pirofski Liise-anne

机构信息

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

出版信息

Clin Vaccine Immunol. 2007 Apr;14(4):382-90. doi: 10.1128/CVI.00374-06. Epub 2007 Feb 14.

Abstract

Antibody-based approaches to pneumococcal disease may hold promise for immunocompromised patients in whom vaccines are less immunogenic and/or in the context of antimicrobial resistance. Antibody-mediated protection against experimental pneumococcal pneumonia has been shown to depend on immunoregulation, but the relationship between antibody and protection against pneumococcal sepsis and immunoregulation has not been examined. Similarly, the requirement for B and T cells for antibody efficacy is not known. In this study, we determined the efficacy of the human pneumococcal capsular polysaccharide serotype 3-specific antibody, A7 (immunoglobulin M [IgM]), in secretory IgM (sIgM)(-/-), CD4(-/-), CD8(-/-), muMT(-/-), and SCID mice and investigated its effect on cytokine and chemokine expression in sera and spleens from mice with intact cellular immunity. A7 is known to be protective against systemic infection with serotype 3 and to require complement for efficacy. Compared to that of an isotype control antibody, A7 administration prolonged the survival of mice of each immunodeficient strain and was associated with a significant reduction in CFU in blood, lung, and spleen samples and a significantly reduced level of keratinocyte-derived chemokine (KC), interleukin-6 (IL-6), and macrophage inflammatory protein-2 (MIP-2) expression in normal and sIgM(-/-) mice. Studies with mice treated with penicillin revealed similar reductions in CFU and similar levels of IL-6, KC, or MIP-2 expression in A7- and penicillin-treated mice. These findings demonstrate that natural IgM and B and T cells are dispensable for A7-mediated protection against experimental pneumococcal sepsis and suggest that the efficacy of antibody-mediated protection depends on immunomodulation. Taken together, our data extend the association between antibody-mediated protection and immunomodulation to protection against systemic pneumococcal infection and to a clinically important serotype often responsible for pneumococcal sepsis.

摘要

基于抗体的肺炎球菌疾病治疗方法可能为免疫功能低下的患者带来希望,这些患者接种疫苗后免疫原性较低,和/或处于抗菌药物耐药的情况下。抗体介导的对实验性肺炎球菌肺炎的保护作用已被证明取决于免疫调节,但抗体与预防肺炎球菌败血症及免疫调节之间的关系尚未得到研究。同样,B细胞和T细胞对抗体疗效的必要性也尚不清楚。在本研究中,我们测定了人肺炎球菌荚膜多糖3型特异性抗体A7(免疫球蛋白M [IgM])在分泌型IgM(sIgM)基因敲除小鼠、CD4基因敲除小鼠、CD8基因敲除小鼠、μMT基因敲除小鼠和重症联合免疫缺陷(SCID)小鼠中的疗效,并研究了其对细胞免疫功能正常的小鼠血清和脾脏中细胞因子及趋化因子表达的影响。已知A7对3型全身性感染具有保护作用,且其发挥疗效需要补体参与。与同型对照抗体相比,给予A7可延长各免疫缺陷品系小鼠的存活时间,并使血液、肺和脾脏样本中的菌落形成单位(CFU)显著减少,同时使正常小鼠和sIgM基因敲除小鼠中角质形成细胞衍生趋化因子(KC)、白细胞介素-6(IL-6)和巨噬细胞炎性蛋白-2(MIP-2)的表达水平显著降低。用青霉素治疗小鼠的研究显示,A7治疗组和青霉素治疗组小鼠的CFU减少程度相似,IL-6、KC或MIP-2的表达水平也相似。这些发现表明,天然IgM以及B细胞和T细胞对于A7介导的预防实验性肺炎球菌败血症并非必需,并提示抗体介导的保护作用的疗效取决于免疫调节。综上所述,我们的数据将抗体介导的保护作用与免疫调节之间的关联扩展至预防全身性肺炎球菌感染以及一种临床上重要的、常导致肺炎球菌败血症的血清型。

相似文献

1
A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection.
Clin Vaccine Immunol. 2007 Apr;14(4):382-90. doi: 10.1128/CVI.00374-06. Epub 2007 Feb 14.
4
The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages.
Vaccine. 2010 Nov 3;28(47):7542-50. doi: 10.1016/j.vaccine.2010.08.061. Epub 2010 Aug 26.
8
Protection against Streptococcus pneumoniae serotype 1 acute infection shows a signature of Th17- and IFN-γ-mediated immunity.
Immunobiology. 2012 Apr;217(4):420-9. doi: 10.1016/j.imbio.2011.10.012. Epub 2011 Nov 23.
9
The immunising effect of pneumococcal nasopharyngeal colonisation; protection against future colonisation and fatal invasive disease.
Immunobiology. 2010 Apr;215(4):251-63. doi: 10.1016/j.imbio.2009.12.004. Epub 2009 Dec 28.

引用本文的文献

1
Diverse Mechanisms of Protective Anti-Pneumococcal Antibodies.
Front Cell Infect Microbiol. 2022 Jan 28;12:824788. doi: 10.3389/fcimb.2022.824788. eCollection 2022.
2
Monoclonal Antibody Requires Immunomodulation for Efficacy Against Acinetobacter baumannii Infection.
J Infect Dis. 2021 Dec 15;224(12):2133-2147. doi: 10.1093/infdis/jiab265.
3
The Other Side of the Coin: Anti-inflammatory Antibody Therapy for Infectious Diseases.
Infect Immun. 2020 Jan 22;88(2). doi: 10.1128/IAI.00844-19.
6
Discrepant serological assays for Pneumococcus in renal transplant recipients - a prospective study.
Transpl Int. 2017 Jul;30(7):689-694. doi: 10.1111/tri.12959. Epub 2017 May 2.
8
IgM-enriched solution BT086 improves host defense capacity and energy store preservation in a rabbit model of endotoxemia.
Acta Anaesthesiol Scand. 2016 Apr;60(4):502-12. doi: 10.1111/aas.12652. Epub 2015 Nov 11.
9
IRAK-4 and MyD88 deficiencies impair IgM responses against T-independent bacterial antigens.
Blood. 2014 Dec 4;124(24):3561-71. doi: 10.1182/blood-2014-07-587824. Epub 2014 Oct 15.
10
Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis.
J Exp Med. 2014 Jun 2;211(6):1243-56. doi: 10.1084/jem.20131471. Epub 2014 May 12.

本文引用的文献

2
Immunomodulators as an antimicrobial tool.
Curr Opin Microbiol. 2006 Oct;9(5):489-95. doi: 10.1016/j.mib.2006.08.004. Epub 2006 Aug 22.
4
Pneumococci induced TLR- and Rac1-dependent NF-kappaB-recruitment to the IL-8 promoter in lung epithelial cells.
Am J Physiol Lung Cell Mol Physiol. 2006 Apr;290(4):L730-L737. doi: 10.1152/ajplung.00271.2005. Epub 2005 Nov 18.
10
The role played by tumor necrosis factor during localized and systemic infection with Streptococcus pneumoniae.
J Infect Dis. 2005 May 1;191(9):1538-47. doi: 10.1086/429296. Epub 2005 Mar 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验